1. Home
  2. REBN vs BCDA Comparison

REBN vs BCDA Comparison

Compare REBN & BCDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Reborn Coffee Inc.

REBN

Reborn Coffee Inc.

HOLD

Current Price

$1.49

Market Cap

8.7M

ML Signal

HOLD

BCDA

BioCardia Inc.

HOLD

Current Price

$1.25

Market Cap

14.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
REBN
BCDA
Founded
2015
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Restaurants
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
8.7M
14.5M
IPO Year
2022
N/A

Fundamental Metrics

Financial Performance
Metric
REBN
BCDA
Price
$1.49
$1.25
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$25.00
AVG Volume (30 Days)
46.1K
99.9K
Earning Date
11-19-2025
11-12-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$6,663,303.00
N/A
Revenue This Year
$335.98
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
21.09
N/A
52 Week Low
$1.20
$1.00
52 Week High
$8.30
$3.20

Technical Indicators

Market Signals
Indicator
REBN
BCDA
Relative Strength Index (RSI) 42.37 43.38
Support Level $1.38 $1.16
Resistance Level $1.55 $1.34
Average True Range (ATR) 0.12 0.09
MACD 0.00 -0.01
Stochastic Oscillator 29.94 26.99

Price Performance

Historical Comparison
REBN
BCDA

About REBN Reborn Coffee Inc.

Reborn Coffee Inc is an operator and franchisor of retail locations and kiosks that focus on serving specialty-roasted coffee. It is an company that strives for constant improvement in the coffee experience through exploration of new technology and premier service, guided by traditional brewing techniques. The company operates in one reportable segment, consisting of both the wholesale and retail sales of coffee, water, and other beverages.

About BCDA BioCardia Inc.

BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an off the shelf cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).

Share on Social Networks: